Treatment interruption patterns and adverse events among patients on bedaquiline containing regimen under programmatic conditions in India.

Abstract

BACKGROUND:

The study aimed to analyze frequency and severity of adverse events (AEs) and other reasons for interruption of treatment and loss to follow up (LTFU) during first six months of treatment among tuberculosis patients on bedaquiline containing regimens.

METHODS:

This pilot exploratory observational study included 275 patients enrolled consecutively over two years who received bedaquiline containing regimen under programmatic conditions in India.

RESULTS:

Among 275 patients with median age of 25 years, 86 (31.3%) patients had at least one interruption with 122 total episodes of interruption. Among these 70 were temporary, 35 were permanent interruptions and 17 were LTFU. The AEs due to drugs were the commonest reason for interruption observed in 81.4% of temporary interruption group and 97.1% of permanent interruption group. Among a total 192 adverse event episodes, (49.5%) were minor (grade 1-2) and (50.5%) were serious (grade 3-5). Personal factors were the commonest reason for interruption observed in LTFU (94.1%) group. The most common temporarily interrupted drug was bedaquiline in 8.7% and permanently stopped drug was linezolid in 5% of patients.

CONCLUSIONS:

Our study observed that drug related AEs are important risk factors associated with treatment interruptions in bedaquiline containing regimens. Bedaquiline is the most common temporarily interrupted drug due to AEs.

• Authors: Sekar Natarajan, Rupak Singla, Neeta Singla, Amitesh Gupta, Jose A Caminero, Amartya Chakraborty, Vikas Kumar
• Journal: Pulmonology (Pulmonology) 2022 May-Jun Vol. 28 Issue 3 Pg. 203-209 ISSN: 2531-0437 [Electronic] Spain
• PMID: 33121945 (Publication Type: Journal Article, Observational Study)
• Copyright: Copyright © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.

Chemical References

• Antitubercular Agents
• Diarylquinolines
• bedaquiline

Topics

• Adult
• Antitubercular Agents (adverse effects)
• Diarylquinolines (adverse effects)
• Humans
• India (epidemiology)
• Tuberculosis, Multidrug-Resistant (drug therapy)